Hims & Hers sued in two class action lawsuits after Novo Nordisk terminates collaboration.

• Hims & Hers Health sued over deceptive marketing and sales concerns • Two securities class action lawsuits filed against the company • Novo Nordisk terminated collaboration with Hims & Hers • Share price crashed 30% after the announcement • Investors may be eligible for substantial losses reimbursement • Hagens Berman investigating legal claims and urges investors to submit losses.

Hims & Hers Health, Inc. (NYSE: HIMS) has been embroiled in legal troubles after two securities class action lawsuits were filed against the company and its executives. The lawsuits, Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.), allege that Hims & Hers made false and misleading statements while failing to disclose crucial information to investors [1].

The lawsuits were filed following an announcement by Novo Nordisk that it terminated its collaboration with Hims & Hers over concerns about the company's sales and "deceptive" marketing of the weight loss drug Wegovy®. This announcement precipitated a 30% crash in the price of Hims & Hers shares [1].

Hagens Berman, a national shareholders' rights firm, is continuing to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit their losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys [1].

The class period for the lawsuits is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1]. Investors who invested in Hims & Hers during this period may be eligible for substantial losses reimbursement.

Novo Nordisk, a global healthcare company, terminated its collaboration with Hims & Hers due to concerns about the company's illegal mass compounding and deceptive marketing of Wegovy®. The company stated, "Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk[]” [1].

Hims & Hers faces significant challenges following the termination of its collaboration with Novo Nordisk. The company's share price has fallen dramatically, and it is now under legal scrutiny for potential deceptive marketing practices. Investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, may be eligible to participate in the securities class action lawsuits [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/11/3114061/32716/en/Hims-Hers-Health-Inc-HIMS-Faces-Securities-Class-Actions-After-Novo-Nordisk-Cancels-Partnership-Over-Deceptive-Marketing-of-Wegovy-Hagens-Berman.html